New asthma medications are currently under development and being tested for their efficacy. They consist of new molecules, agents and compounds. Currently there are several under clinical trials or phases. Each phase is designed to answer a separate question.
Phase 1-Where researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, identify side effects and to determine a safe dosage range.
Phase 2-The new drug is given to a large group of people to see if its effective and to further evaluate its safety.
Phase 3-The drug is given to an even larger group of people to monitor side effects, confirm that it is effective, compare it to other medications used to treat the condition, and collect more information on the drugs safety.
Phase 4-Studies are done after the drug is marketed to gather information on long term side effects and how it affects specific populations.
AMG 282. This is a monoclonal antibody being developed by Amgen. It is a monoclonal antibody that inhibits binding of IL-33. It is being study for asthma and chronic rhinosinusitis with polyps.
AMG 157. This is being developed by Amgen and AstraZeneca, it is a monoclonal antibody that inhibits TSLP (thymic stromal lymphopoeitin) and its being tested for asthma treatment. Early studies shows it reduces allergen induced bronchoconstriction and airway inflammation.
Lebrikizumab. This is a human monoclonal antibody being studied for asthma. It blocks IL-13, a cytokine produced by white blood cells that is thought to induce the expression of Periostin, which can cause a number of asthma related problems. This new asthma medication would treat patients who don’t respond well to inhaled steroids. To read more about Lebrikizumab, you can click on the link below.
Benralizumab. This is an Anti-IL-5R (CD 125) monoclonal antibody being studied for severe asthma. Early studies have showed a reduction of asthma exacerbations. It is also being studied for COPD (Chronic Obstructive Pulmonary Disease), but results have not been as promising as its been for asthma. Blocking the IL-5 Receptor, depletes the blood and airway of eosinophils, which would make it ideal for eosinophilic asthma.
Dupilumab is also being studied for asthma in addition to atopic dermatitis. Dupilumab
Asthma sufferers may have a plethora of choices with all of these new asthma medications in the future. As always speak to your asthma and allergy doctor about which medication may be right for you.